No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IVVD240621P5000
- 3.30
- 0.000.00%
15min DelayClose Jun 14 16:00 ET
0.00High0.00Low
3.30Open3.30Pre Close0 Volume7 Open Interest5.00Strike Price0.00Turnover525.41%IV-7.59%PremiumJun 21, 2024Expiry Date3.42Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9143Delta0.1494Gamma0.46Leverage Ratio-0.0122Theta-0.0006Rho-0.42Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Express News | Invivyd- Sars-Cov-2 Mab Candidate, Vyd2311 Shows Continued in Vitro Neutralization Activity in Pseudovirus Assays Against Kp.1.1 Flirt, Kp.3 Variants
Express News | Invivyd: Pseudovirus in Vitro Neutralization Data Show Continued Neutralizing Activity of Vyd222 (Pemivibart) Against Kp.1.1 Flirt & Kp.3 Sars-Cov-2
Express News | Invivyd Announces Antiviral Activity of Vyd222 (Pemivibart) Against Sars-Cov-2 Kp.1.1 Flirt & Kp.3 Variants
Invivyd to Participate at the Jefferies Global Healthcare Conference
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management
Invivyd(IVVD.US) Director Sells US$186.57K in Common Stock
$Invivyd(IVVD.US)$ Director MCGUIRE TERRANCE sold 112.38K shares of common stock on May 29, 2024 at an average price of $1.6602 for a total value of $186.57K.Source: Announcement What is statement of
Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment
Comments
$Invivyd(IVVD.US$ Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
• Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies (mAbs) to prevent and t...
• Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies (mAbs) to prevent and t...
1
$Invivyd(IVVD.US$
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
Invivyd announced its upcoming presentations at the 2024 ASCO Annual Meeting and the 2024 ATC. The presentations will cover preliminary subset analyses from the Phase 3 CANOPY trial of VYD222 (pemivibart), a monoclonal antibody aimed at preventing COVID-19.
At ASCO (May 31 – June 4, Chicago, IL), the focus will be on participants with sign...
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
Invivyd announced its upcoming presentations at the 2024 ASCO Annual Meeting and the 2024 ATC. The presentations will cover preliminary subset analyses from the Phase 3 CANOPY trial of VYD222 (pemivibart), a monoclonal antibody aimed at preventing COVID-19.
At ASCO (May 31 – June 4, Chicago, IL), the focus will be on participants with sign...
$Invivyd(IVVD.US$ Benzinga· just
Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback
Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback
$Invivyd(IVVD.US$ Invivyd Receives Healthcare Common Procedure Coding System (Hcpcs) Reimbursement Codes From the U.S. Centers for Medicare & Medicaid Services (CMS) Covering Pemgarda™
$Invivyd(IVVD.US$ Invivyd Shares Are Trading Higher After the Company Announced PEMGARDA Is Available for Purchase in the U.S. and Said It Sees Initial FY24 PEMGARDA Net Product Revenue Guidance in the Range of $150 Million to $200 Million
2
1
Read more